- Home
- ARKO vs DRUG Comparison
ARKO vs DRUG Comparison
Compare ARKO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARKO
- DRUG
- Stock Information
- Founded
- ARKO 1970
- DRUG 2019
- Country
- ARKO United States
- DRUG United States
- Employees
- ARKO N/A
- DRUG N/A
- Industry
- ARKO Oil Refining/Marketing
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ARKO Energy
- DRUG Health Care
- Exchange
- ARKO Nasdaq
- DRUG Nasdaq
- Market Cap
- ARKO 453.2M
- DRUG 364.8M
- IPO Year
- ARKO N/A
- DRUG N/A
- Fundamental
- Price
- ARKO $4.36
- DRUG $56.97
- Analyst Decision
- ARKO Buy
- DRUG Strong Buy
- Analyst Count
- ARKO 3
- DRUG 9
- Target Price
- ARKO $7.50
- DRUG $81.67
- AVG Volume (30 Days)
- ARKO 433.5K
- DRUG 196.2K
- Earning Date
- ARKO 11-05-2025
- DRUG 12-30-2025
- Dividend Yield
- ARKO 2.75%
- DRUG N/A
- EPS Growth
- ARKO N/A
- DRUG N/A
- EPS
- ARKO 0.11
- DRUG N/A
- Revenue
- ARKO $7,887,822,000.00
- DRUG N/A
- Revenue This Year
- ARKO N/A
- DRUG N/A
- Revenue Next Year
- ARKO N/A
- DRUG N/A
- P/E Ratio
- ARKO $40.09
- DRUG N/A
- Revenue Growth
- ARKO N/A
- DRUG N/A
- 52 Week Low
- ARKO $3.51
- DRUG $23.18
- 52 Week High
- ARKO $7.84
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- ARKO 49.69
- DRUG 49.89
- Support Level
- ARKO $4.26
- DRUG $55.01
- Resistance Level
- ARKO $4.48
- DRUG $61.81
- Average True Range (ATR)
- ARKO 0.19
- DRUG 3.80
- MACD
- ARKO 0.01
- DRUG -0.06
- Stochastic Oscillator
- ARKO 68.33
- DRUG 61.06
About ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.